Through rigorous primary research, deep sector expertise, and our proprietary Life Science Panel, we provide evidence that gives organizations confidence in the decisions they make.
Our approach combines quantitative and qualitative research with specialist knowledge of pharmaceutical outsourcing. From competitive benchmarking and brand perception to buyer behavior and market dynamics, we help organizations understand how they compare, what influences complex B2B vendor selection and procurement decisions, and where opportunities for differentiation may exist.
Our syndicated studies uncover the perspectives, experiences, and expectations shaping pharmaceutical outsourcing.
Every report is developed by researchers who interpret the industry through the lens of real-world market knowledge, helping clients understand what the findings mean.
Give your entire organization access to ISR’s market intelligence, so teams can work from the same trusted research and make aligned, informed decisions.
Whether you’re looking to assess brand perception, explore new market opportunities, or uncover factors influencing purchasing decisions, we work closely with you to identify the questions that matter most and design the right research approach.
Supported by our proprietary Life Science Panel and extensive sector expertise, custom research provides evidence tailored to your specific goals and in the context of your business objectives.
The partnership brings together ISR’s proprietary benchmarking and market intelligence with ramarketing’s brand strategy and marketing expertise – so life sciences organizations can move more confidently from research insight to impactful action.
Same rigorous research, now with the strategic expertise to help you act on it.
Every study is designed, challenged, and interpreted by specialists who understand pharmaceutical outsourcing.
Research is most valuable when findings are understood. We help clients interpret evidence, identify implications, and connect data to decisions.
Choosing an outsourcing partner for a commercial bioprocessing endeavor carries a gravitas that those outside that endeavor may not appreciate. Equally significant is the challenge facing CMOs in this space, many of whom are competing against larger, well-known manufacturers with…
I bet you can’t say “cell & gene therapies” three times fast. And by the time you do, you’ll have missed another article on your newsfeed discussing their intricacies and the headaches they can cause. Here’s one from Industry Standard…
ISR’s CTMS Benchmarking & Market Dynamics (3rd Ed.) aims to tackle clinical trial management systems (CTMS) by helping providers and sponsors alike better understand current trends surrounding this technology and anticipate future ones. This report is the result of primary…
© 2026 ISR Market Research. All rights reserved.
